News

 

NerPharMa Appoints Claudio Salvagnini as Deputy CEO

NerPharMa Appoints Claudio Salvagnini as Deputy CEO

Nerpharma is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.

Since Claudio joined the leadership team earlier this year, he has been a driving force in the recent turning around NerPharMa. As the Deputy CEO, he will play a critical role in shaping the company’s strategic direction and ensuring operational efficiency.

(Click the title for the complete article)

NerPharMa Appoints Vittorio Montanaro as New Head of Quality to Strengthen Commitment to Excellence

NerPharMa Appoints Vittorio Montanaro as New Head of Quality to Strengthen Commitment to Excellence

NerPharMa Srl (part of NMS group), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Vittorio Montanaro as new Head of Quality, effective immediately. In this role, Vittorio will lead the Quality Assurance, Quality Control and Regulatory Affairs to ensure the highest standards of quality, safety and compliance across NerPharMa’s extensive range of services, offered through both Drug Substances and Drug Product divisions. Vittorio will cover also the role of Qualified Person.

(Click the title for the complete article)

NMS Group certified as “Workplace that promotes health initiatives” again in 2022

NMS Group certified as “Workplace that promotes health initiatives” again in 2022

NMS group has joined the WHP program since 2017. The Workplace Health Promotion (WHP) is the combined efforts of employers, employees and society to improve the health and well-being of people at work. The promotion of a comfortable and healthy workplace has been one of the goals of NMS group since 2017.
(Click the title for the complete article)

NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth

NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth

NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.
(Click the title for the complete article)

NerPharMa Srl Announces Change in Board Composition Effective Today

Nerviano_October_1_2022_NerPharMa Srl, leading CMO and a member of the NMS Group today announced the change in its Board Composition, following the resignation of its board member Enrico Pesenti, effective today. Hugues Dolgos, Pharm.D., CEO of NMS Group, is appointed as Sole Director of NerPharMa Srl.   
(Click the title for the complete article)

Nerviano Medical Sciences signs research agreement with Università del Piemonte Orientale, Faculty of Pharmaceutical Sciences

Nerviano, 28 June 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of Pharmaceutical Sciences in Novara (DSF), as part of the National Operational Programme on Research and Innovation 2014-2020 (Programma Operativo Nazionale (PON) – “RICERCA E INNOVAZIONE” 2014-2020). The Programme is the key instrument with which the Italian government contributes to the improvement of the quality of higher education and the enhancement of research, technological development and innovation.
(Click the title for the complete article)

BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer.

Nerviano, 31 May 2022
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer. BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari: Transport Oncophysics. BrYet will collaborate with our strategic production partner NerPharMa, a leading CDMO in oncology, to scale-up the drug substance manufacturing process and the finished product to supply material for clinical programs with potential upside to future world-wide commercial sales. The company’s goal is to start ML-016 clinical trials in the second half of 2023.
(Click the title for the complete article)

NMS Group S.p.A. Announces Resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl; Hugues Dolgos – CEO of NMS Group S.p.A. – Appointed Interim CEO

Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly. (Click the title for the complete article)

Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy

Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy

Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the Health Commission of Lombardy Region, Mr. Loredano Pollegioni, Chairman of FRRB (Fondazione Regionale per la Ricerca Biomedica), Mr. Luigi Cajazzo, Managing director of FRRB and Mr. Massimiliano Amato, Board member of NMS Group SpA today. The delegation was warmly welcomed by Dr. Hugues Dolgos, the newly appointed CEO of NMS Group and CEOs of the Group’s subsidiaries Dr. Guoxian (Gregory) Wu, Mr. Angelo Colombo, and Mr. Giuseppe Vivolo. (Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO